Cost of medicines from Canada set to soar for millions of Americans

Millions of Americans who purchase affordable medications from Canadian pharmacies may soon face increased costs due to a new U.S. Customs and Border Protection rule set to take effect later this month. The rule suspends the de minimis exemption, which previously allowed packages valued under $800 to be imported duty-free. This exemption is particularly significant for those who rely on lower-cost drugs from Canada.

Susan Hooper, a 75-year-old resident of Toledo, Ohio, is among those affected. She takes two daily medications purchased through a Canadian pharmacy, which are not available in the U.S. Hooper expressed her concern that the issue is a matter of life and death for her. The de minimis exemption applies to a wide range of goods, not just pharmaceuticals, but the practical consequences will be most felt by those who purchase their drugs from overseas.

According to a 2020 study by JAMA Network, approximately 2.3 million Americans buy their medications abroad. The Trump administration has made lowering drug prices a priority, but the impact of its policies on drug prices remains complex. Critics argue that the new rule will hinder patients seeking affordable medications. Ken Hunter, executive director of the Campaign for Personal Prescription Importation, warns that costs will skyrocket for some medications after a study revealed that mail-order Canadian pharmacies offer significantly lower prices compared to U.S. retailers.

Advocates urge the administration to reconsider the rule and explore alternative solutions to protect access to affordable healthcare. Some lawmakers have expressed concern about the rule's potential impact on constituents who rely on Canadian drug imports. While the White House maintains its commitment to lowering drug prices, the future of this rule remains uncertain.